NASDAQ:INFIInfinity Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Infinity Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.87 -0.02 (-2.25 %) (As of 06/4/2020 12:13 PM ET) Add Compare Share Today's Range$0.87Now: $0.87▼$0.8950-Day Range$0.88MA: $0.99▼$1.1352-Week Range$0.60Now: $0.87▼$1.80Volume2,475 shsAverage Volume158,100 shsMarket Capitalization$49.96 millionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingInfinity Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.17, Infinity Pharmaceuticals has a potential upside of 149.0% from its current price of $0.87.Amount of Analyst CoverageInfinity Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Community Rank Outperform VotesInfinity Pharmaceuticals has received 350 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInfinity Pharmaceuticals has received 529 “underperform” votes. (Add your “underperform” vote.)Community SentimentInfinity Pharmaceuticals has received 60.18% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote “Outperform” if you believe INFI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInfinity Pharmaceuticals does not currently pay a dividend.Dividend GrowthInfinity Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Infinity Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.12% of the stock of Infinity Pharmaceuticals is held by insiders.Percentage Held by Institutions48.68% of the stock of Infinity Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Infinity Pharmaceuticals are expected to decrease in the coming year, from ($0.76) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Infinity Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Infinity Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInfinity Pharmaceuticals has a P/B Ratio of 6.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.28 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INFI Previous Symbol CUSIP45665G30 CIK1113148 Webwww.infi.com Phone617-453-1000Debt Debt-to-Equity Ratio0.25 Current Ratio6.27 Quick Ratio6.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.05 million Price / Sales16.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book6.21Profitability EPS (Most Recent Fiscal Year)($0.83) Net Income$-47,060,000.00 Net Margins-3,308.31% Return on Equity-329.49% Return on Assets-75.67%Miscellaneous Employees25 Outstanding Shares57,430,000Market Cap$49.96 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:INFI Rates by TradingView Receive INFI News and Ratings via Email Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter. Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions How has Infinity Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INFI stock has decreased by 13.9% and is now trading at $0.87. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Infinity Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Infinity Pharmaceuticals. When is Infinity Pharmaceuticals' next earnings date? Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Infinity Pharmaceuticals. How were Infinity Pharmaceuticals' earnings last quarter? Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.06. The biotechnology company earned $0.43 million during the quarter, compared to analyst estimates of $0.25 million. Infinity Pharmaceuticals had a negative net margin of 3,308.31% and a negative return on equity of 329.49%. View Infinity Pharmaceuticals' earnings history. What price target have analysts set for INFI? 4 brokerages have issued 1 year price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they expect Infinity Pharmaceuticals' share price to reach $2.17 in the next year. This suggests a possible upside of 149.0% from the stock's current price. View analysts' price targets for Infinity Pharmaceuticals. Has Infinity Pharmaceuticals been receiving favorable news coverage? Media headlines about INFI stock have been trending very negative on Thursday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutInfinity Pharmaceuticals. Are investors shorting Infinity Pharmaceuticals? Infinity Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 33,300 shares, a decrease of 8.0% from the April 30th total of 36,200 shares. Based on an average daily trading volume, of 160,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's stock are sold short. View Infinity Pharmaceuticals' Current Options Chain. Who are some of Infinity Pharmaceuticals' key competitors? Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Infinity Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ImmunoGen (IMGN), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Bausch Health Companies (BHC). Who are Infinity Pharmaceuticals' key executives? Infinity Pharmaceuticals' management team includes the following people: Ms. Adelene Q. Perkins, Chairman & CEO (Age 59)Dr. Lawrence E. Bloch, Pres & Treasurer (Age 53)Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 52)Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 40)Ms. Melissa Hackel, VP of Fin. What is Infinity Pharmaceuticals' stock symbol? Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI." Who are Infinity Pharmaceuticals' major shareholders? Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (1.03%) and Bleichroeder LP (0.00%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View institutional ownership trends for Infinity Pharmaceuticals. Which institutional investors are selling Infinity Pharmaceuticals stock? INFI stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, and Acadian Asset Management LLC. View insider buying and selling activity for Infinity Pharmaceuticals. How do I buy shares of Infinity Pharmaceuticals? Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Infinity Pharmaceuticals' stock price today? One share of INFI stock can currently be purchased for approximately $0.87. How big of a company is Infinity Pharmaceuticals? Infinity Pharmaceuticals has a market capitalization of $49.96 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe. What is Infinity Pharmaceuticals' official website? The official website for Infinity Pharmaceuticals is www.infi.com. How can I contact Infinity Pharmaceuticals? Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
